Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for keloid scars; and SNT-4728 to treat sleep disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates that target fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Name | Title | Since | Age |
|---|---|---|---|
| Kathleen M. Metters | Independent Non Executive Chair | 2023 | 69 |
| Gary Jonathan Phillips | CEO, MD & Director | 2013 | 65 |
| Simon P. Green | Independent Non-Executive Director | 2022 | - |
| Waradana Malitha Hashan De Silva | Non-Executive Director | 2023 | - |
| Claire Harrison | Member of Clinical Advisory Board | 2025 | - |
| John Mascarenhas | Member of Clinical Advisory Board | 2025 | - |
| Kevin Patrick Lynch | Member of Clinical Advisory Board | 2025 | 61 |
| Adam R. Craig | Member of Clinical Advisory Board | 2025 | 60 |
| Gaby Hobbs | Member of Clinical Advisory Board | 2025 | - |